GERN - Geron Corporation

-

$undefined

N/A

(N/A)

Geron Corporation NASDAQ:GERN Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Location: 919 East Hillsdale Boulevard, Suite 250, California, 94404, US | Website: www.geron.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.292B

Cash

362.7M

Avg Qtr Burn

-51.88M

Short % of Float

14.18%

Insider Ownership

0.09%

Institutional Own.

78.24%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.